Carlo Incerti Biography and Net Worth

Director of Dyne Therapeutics

Carlo has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. Carlo is currently an operating partner at Forbion, a life sciences venture capital firm. Previously, he held several positions of increasing responsibility during his more than 25 years at Sanofi Genzyme, including senior vice president, chief medical officer and head of global medical affairs. He also served as senior vice president of global market access and held various roles at Genzyme’s European headquarters. He is chairman of the Board at Azafaros B.V., VectorY Therapeutics, and Numab Therapeutics AG. Previously Carlo served on the board of directors at EryDel SpA and Inversago Pharma. Carlo is also a founding member of the International Rare Diseases Research Consortium.

He received his medical degree from the University of Modena and Reggio Emilia, Italy.

How do I contact Carlo Incerti?: The corporate mailing address for Dr. Incerti and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at ir@dyne-tx.com. Learn More on Carlo Incerti's contact information.
Has Carlo Incerti been buying or selling shares of Dyne Therapeutics?: Carlo Incerti has not been actively trading shares of Dyne Therapeutics during the last quarter. Most recently, Carlo Incerti sold 16,500 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a transaction totalling $474,045.00. Learn More on Carlo Incerti's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 1 times. They purchased a total of 32,000 shares worth more than $1,057,280.00. During the last year, insiders at the sold shares 25 times. They sold a total of 388,416 shares worth more than $12,878,411.80. The most recent insider tranaction occured on March, 13th when insider Johanna Friedl-Naderer sold 143 shares worth more than $1,733.16. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 3/13/2025.

Carlo Incerti Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2024	Sell	16,500	$28.73	$474,045.00

Carlo Incerti Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $8.28

$8.15

$9.40

50 Day Range

MA: $12.92

$9.23

$16.76

2 Week Range

Now: $8.28

$8.15

$47.45

Volume

2,602,714 shs

Average Volume

1,424,942 shs

Market Capitalization

$936.64 million

P/E Ratio

N/A

Dividend Yield